Biotech | July 07, 2025
Godavari Biorefineries' anti-cancer patent now validated in Spain and UK
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
The IND application supports the next phase of development of SBO-154
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
